Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03430518
Title Durvalumab and Eribulin in Her2-negative Metastatic Breast Cancer and Recurrent Ovarian Cancer
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Amy Tiersten

Her2-receptor negative breast cancer

ovary epithelial cancer


Durvalumab + Eribulin

Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.